NYX-783, Emerging Drug Insight and Market Forecast – 2032

NYX-783, Emerging Drug Insight and Market Forecast – 2032

“NYX-783, Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about NYX-783 for Post-traumatic Stress Disorder in seven major markets. A detailed picture of the NYX-783 for Post-traumatic Stress Disorder in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the NYX-783 for Post-traumatic Stress Disorder. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NYX-783 market forecast analysis for Post-traumatic Stress Disorder in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Post-traumatic Stress Disorder.

Drug Summary

NYX-783 is a novel, oral and small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR) that is being developed by Aptinyx for Post-traumatic Stress Disorder. In preclinical studies of NYX-783, particularly strong results were observed in psychiatric models, models of fear extinction, and models of substance abuse. NYX-783 is in Phase 2b clinical development for the treatment of post-traumatic stress disorder, or Post-traumatic Stress Disorder. The company is currently enrolling in a Phase 2b study evaluating the efficacy and safety of a 50 mg dose of NYX-783 in approximately 300 patients with Post-traumatic Stress Disorder. On April 19, 2022, the company announced a temporary pause of the initiation of a second Phase 2b study evaluating a 150 mg dose of NYX-783 in patients with Post-traumatic Stress Disorder. The 150 mg study had not enrolled any patients at the time of the announcement and the study initiation was paused to conserve capital and extend the operational runway.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the NYX-783 description, mechanism of action, dosage and administration, research and development activities in Post-traumatic Stress Disorder.

Elaborated details on NYX-783 regulatory milestones and other development activities have been provided in this report.

The report also highlights the NYX-783 research and development activities in Post-traumatic Stress Disorder across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around NYX-783.

The report contains forecasted sales of NYX-783 for post-traumatic stress disorder till 2032.

Comprehensive coverage of the late-stage emerging therapies for Post-traumatic Stress Disorder.

The report also features the SWOT analysis with analyst views for NYX-783 in Post-traumatic Stress Disorder.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NYX-783 Analytical Perspective by DelveInsight

In-depth NYX-783 Market Assessment

This report provides a detailed market assessment of NYX-783 for post-traumatic stress disorder in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

NYX-783 Clinical Assessment

The report provides the clinical trials information of NYX-783 for Post-traumatic Stress Disorder covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for post-traumatic stress disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NYX-783 dominance.

Other emerging products for Post-traumatic Stress Disorder are expected to give tough market competition to NYX-783 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NYX-783 in Post-traumatic Stress Disorder.

Our in-depth analysis of the forecasted sales data of NYX-783 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NYX-783 in Post-traumatic Stress Disorder.

Key Questions

What is the product type, route of administration and mechanism of action of NYX-783?

What is the clinical trial status of the study related to NYX-783 in post-traumatic stress disorder and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NYX-783 development?

What are the key designations that have been granted to NYX-783 for Post-traumatic Stress Disorder?

What is the forecasted market scenario of NYX-783 for Post-traumatic Stress Disorder?

What are the forecasted sales of NYX-783 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to NYX-783 for Post-traumatic Stress Disorder?

Which are the late-stage emerging therapies under development for the treatment of Post-traumatic Stress Disorder?